An enzymatic approach reverses nicotine dependence, decreases compulsive-like intake, and prevents relapse

Area of Science:

• Pharmacology
• Neuroscience
• Biotechnology

Background:

• Tobacco use disorder is a leading global health issue with limited effective treatments.
• Current pharmacodynamic medications for nicotine addiction have low efficacy.
• Previous pharmacokinetic approaches using vaccines failed due to insufficient antibody concentration and affinity.

Purpose of the Study:

• To evaluate the efficacy of an enzymatic approach for reversing nicotine dependence.
• To assess the ability of an engineered enzyme to reduce compulsive nicotine intake and prevent relapse.
• To provide preclinical evidence for a novel biological therapy for smoking cessation.

Main Methods:

• Administration of NicA2-J1, an engineered nicotine-degrading enzyme from *Pseudomonas putida* S16, to nicotine-dependent rats.
• Assessment of nicotine levels in the brain.
• Evaluation of somatic withdrawal signs, hyperalgesia, and irritability-like behaviors.
• Measurement of compulsive-like nicotine intake despite adverse consequences (footshocks).
• Testing of relapse prevention following nicotine or stress (yohimbine) challenges.

Main Results:

• Chronic NicA2-J1 administration completely prevented nicotine from reaching the brain.
• The enzyme reversed somatic signs of withdrawal, hyperalgesia, and irritability-like behavior.
• NicA2-J1 decreased compulsive-like nicotine intake and prevented relapse induced by nicotine or yohimbine.
• The therapy was effective in rats with a history of escalated nicotine self-administration.

Conclusions:

• Enzymatic therapy with NicA2-J1 demonstrates efficacy in reversing nicotine dependence in advanced animal models.
• This approach successfully reduces compulsive nicotine use and prevents relapse.
• Enzymatic therapy offers a promising foundation for developing novel biological treatments for smoking cessation in humans.